WWW.IJRPR.COM

International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

A Review Gene Therapy

Advances in Gene Therapy: Novel Strategies for Targeted Gene Delivery and Therapeutic Applications

Jadhav Shwetali, Dipali Shegar, Nilima Ghuge, Vaishanvi Nagare

College-Matoshri Institute of Pharmcy Dhanore, Yeola, Department of Pharmcy, Nashik, India, Maharashtra
E-mail I'd -shwetalijadhav07@gmail.com

ABSTRACT-

Over the past 25 years, gene therapy has revolutionized the treatment of genetic disorders and diseases. This review delves into its evolution, objectives, and scope. By introducing functional genes, gene therapy aims to correct genetic defects, potentially offering long-term therapeutic benefits. Recent technological breakthroughs have enabled researchers to target previously inaccessible organs and genetic anomalies, showing remarkable progress in treating neurodegenerative disorders. Gene therapy has become a crucial component of therapeutic strategies for inherited and acquired human diseases, offering personalized treatments that could transform medicine. Future research focuses on identifying suitable targets, refining delivery methods, managing immune responses, ensuring regulatory control, and minimizing side effects to enhance efficacy and safety. The ongoing advancements and potential of gene therapy bring hope for improved patient outcomes and quality of life. In cancer treatment, gene therapy shows promise in delivering essential proteins and regulating gene expression, potentially replacing traditional treatments for long-term benefits. While significant progress has been made in treating monogenetic diseases, challenges remain for common conditions like cystic fibrosis and muscular dystrophy. Modified adenoviruses are being explored as effective gene delivery vehicles to overcome these challenges. Ensuring the safety and efficacy of gene therapy products during clinical trials requires adherence to principles of chemistry, manufacturing, and control (CMC) and quality assurance. The integration of gene therapy with technologies like CRISPR-Cas9 opens up exciting opportunities for precision medicine, marking a significant milestone in personalized and targeted healthcare.

Index Terms— Gene, development, CRISPR-Cas9, barriers, cancer, DNA, RNA

Introduction:

Gene therapy is a promising alternative to conventional treatments for genetic disorders, aiming to modify malfunctioning genetic expression for lasting effects. Successful gene therapy relies on delivering therapeutic genes across biological barriers to the target location. However, direct introduction of bare nucleic acids has limitations due to rapid clearance and loss of expression. Therefore, researchers are investigating various delivery vehicles to encapsulate genetic material during transportation.

Progress in Gene Therapy:

Gene therapy has shown significant progress in treating neurodegenerative disorders over the past few decades. Advancements in technology, understanding of disease mechanisms, and identification of therapeutic targets and vectors have contributed to this progress. Genetic interventions can now effectively target the root causes of these disorders, whether they have single-gene or complex origins.

Benefits of Gene Therapy:

The sustained and potentially permanent therapeutic effects of gene therapy are particularly beneficial for treating difficult-to-reach organs like the eye, cochlea, and central nervous system. Gene therapy can also manage genetic targets that traditional treatments cannot handle, allowing for gene silencing to address gain of function mutations and gene overexpression to handle loss of function mutations.

Definition of Gene Therapy:

Gene therapy is a technique that modifies and develops a person's genes to treat or cure diseases or disorders. It can work through various mechanisms, such as replacing a disease-causing gene with a healthy copy of the gene. By introducing functional genes into the patient's cells, gene therapy aims to correct genetic abnormalities and restore normal cellular function.

Applications of Gene Therapy:

Successful gene therapy is not limited to genetic diseases. It has various applications, including:

- Treating cancer patients with T cells that can recognize and kill cells bearing tumor-specific antigens

- Using Autologous CD8+ T cells that are engineered to recognize and kill cells bearing tumor-specific antigens through a CAR that combines the specificity of a monoclonal antibody with the proliferative and cytotoxic abilities of an activated T cell.

1.Historical Context:

The concept of gene therapy, introduced nearly five decades ago, revolutionized the approach to treating inherited human diseases. Pioneering scientists envisioned using exogenous DNA to modify genes, offering a potentially curative and lasting solution through a single treatment. Despite initial promise, gene therapy faced numerous setbacks over the next three decades. However, recent years have seen significant advancements in genome editing technologies, built upon engineered or bacterial nucleases. A pivotal moment came in 1996 when an NIH advisory panel identified the primary obstacles hindering gene therapy's success: a limited understanding of viral vectors, target cells and tissues, and the diseases being treated. This recognition sparked a renewed focus on addressing these challenges, paving the way for gene therapies to become a vital component in treating a range of inherited and acquired human diseases.

2.Aims and scope -

The Journal of Drug Delivery and Therapeutics is a peer-reviewed publication catering to academic and industrial researchers in Pharmaceutical Science and Therapeutics. It encompasses Medical Sciences (medicine, surgery, ophthalmology, gynaecology and obstetrics, paediatrics, orthopaedics, microbiology, pathology and laboratory medicine, medical education, medical ethics, community medicine and public health, anatomy, physiology, pharmacology) and Pharmaceutical Sciences (Biotechnology, Biochemistry, DRA, Phytomedicine/Ayurveda, Pharmaceutics, Drug Delivery, Pharmaceutical Chemistry, Pharmaceutical Analysis). [4]

India's gene therapy research rapidly improved with government financial assistance, now ranking third among major Asian countries with gene therapy laboratories.

Gene therapy's publication growth remained stagnant despite a 6% annual rise in authors, indicating limited appeal and low research activity.[5]

The scope of gene therapy is vast and encompasses a wide range of genetic and acquired diseases. It holds promise in treating various genetic disorders, such as cystic fibrosis, muscular dystrophy, sickle cell anaemia, and inherited metabolic disorders.

3.Future Objectives:

1. *Target identification*: Selecting suitable targets for gene therapy to ensure precise treatment.

2. *Specific delivery*: Delivering therapeutic transgenes to the intended cells, in the optimal amount, while avoiding off-target effects.

3. *Vector optimization*: Developing vectors that evade immune responses and prevent reversion to pathogenic forms, ensuring safe and effective transgene delivery.

4. *Regulatory control*: Incorporating appropriate regulatory elements to govern transgene expression, enabling precise control over gene activation and deactivation.

5. *Transgene persistence*: Ensuring the transgene remains in the target cell for a sufficient duration to achieve therapeutic efficacy.

6. *Safety and specificity*: Preventing unintended consequences, such as neoplasm development or autoimmune responses, by avoiding transgene expression that could introduce novel proteins to the patient's body.

4.In the next 25 years, gene therapy is likely to revolutionize the treatment of various diseases. We can expect:

1. _Sustained protein delivery_: Gene therapy will provide essential proteins for extended periods, potentially protecting against diseases and aiding in cancer and autoimmune disease treatment.

2. _Targeted and controlled delivery_: Gene therapy will be delivered to specific sites, reducing side effects, and controlled using small molecules for safe treatment.

3. _Replacement of traditional treatments_: Gene therapy may replace traditional treatments, such as using genes to regulate insulin for type 1 diabetes.

4. _Direct gene correction_: Gene editing will enable direct correction of inherited single-gene issues, requiring specialized treatments for each condition.

5. _Treatment of complex diseases_: Gene therapy will target common diseases like heart disease and cancer, with injectable delivery methods becoming more prevalent.

6. _Improved viral vector manufacturing_: Better methods for creating and purifying viral carriers will be crucial for scaled-up gene therapy production.

Gene therapy holds immense promise for the future, and ongoing research and development will help address the remaining challenges and bring these advancements to fruition.

5.TCR Gene-Modified T Cells for Cancer Immunotherapy:

Gene transfer of cloned TCRs from tumor-infiltrating T cells is another approach for T-cell-based cancer immunotherapy, especially for tumor antigens not expressed on the cell surface. In TCR gene therapy, the patient's T cells are engineered ex vivo to target a specific tumor antigen. These engineered T cells recognize tumor antigen in the context of HLAs in the tumor microenvironment. Clinical trials have employed genetically modified TCRs to treat various cancers, including synovial cell sarcoma, neuroblastoma, melanoma, and colorectal cancer, with long-term tumor regression.

*CRISPR-Cas9 Gene-Editing Technology:

CRISPR-Cas9 is a revolutionary gene-editing technology that enables targeted modifications in DNA sequences. Originally part of the bacterial immune system, CRISPR-Cas9 has been adapted for precise and efficient gene editing in various organisms, including humans. This technology has opened up new possibilities for treating genetic diseases, advancing agricultural practices, and conducting fundamental research in genetics and biology.

6.Gene Therapy in Cancer Treatment:

Gene therapy has emerged as a promising approach in treating various diseases, particularly cancer. Cancer is a major focus for gene therapy research and development due to its prevalence and devastating impact. The ability to target specific genetic mutations and cellular pathways associated with cancer has revolutionized the field, offering new avenues for treatment.

Promising clinical data from early trials have provided encouraging results, further fueling the momentum behind gene therapy as a potentially transformative cancer treatment. Gene therapies possess all the profiles required for advances in cancer therapy, including:

- Novel therapeutic agent with a unique mode of action.

- Multiple mechanisms of cell death.

- Potential for synergy with conventional management.

- Targeting the disruption of normal cell proliferation and apoptosis process that underlies cancer development.

Recent progress in gene therapy has been fueled by the identification of bone marrow stem cell populations and the successful transduction of other long-lived hematopoietic cells, making this approach feasible for testing in clinical trials. Several recent reviews have summarized the advancements in gene therapy, highlighting significant developments in the field.

7.Challenges of Gene Therapy in Cancer Treatment:

Despite encouraging outcomes from initial clinical trials, gene therapy in cancer treatment faces several challenges. For instance:

1. Delivery limitations: The delivery of the HF10 virus for breast cancer patients has been restricted to local-regional administration, and the assessment of systemic effects is still pending.

2. Cancer cell stimulation: Breast cancer cells can stimulate the secretion of chemokine CCL5 from mesenchymal stem cells, enhancing cancer cell motility, invasion, and metastasis.

3. Latency period: Cancer has a lengthy latency period, making it challenging to detect and diagnose. However, this extended timeframe offers opportunities for modifying genetic damage through gene replacement or introducing tumor-suppressing genes.

4. Peer review process: Cancer Gene Therapy (CGT) has adapted its peer review process to accommodate the challenges faced by investigators.

8.Adenoviruses as Gene-Delivery Vehicles:

Gene therapy requires effective and safe ways to deliver therapeutic genes into cells. Adenoviruses have shown promise as gene-delivery vehicles due to their ability to target various cell types, including non-dividing cells. Scientists have modified adenoviruses to reduce their ability to cause infections and replicate inside the body.

Initial studies used first-generation adenoviral vectors to treat cystic fibrosis, a genetic condition affecting lung function. While these vectors showed promise, they had limitations, including temporary gene expression and immune responses that reduced their effectiveness.

To address these issues, researchers have modified the vectors to reduce immune responses and are exploring combination strategies with immunosuppressive medications. However, there is ongoing debate about the efficiency of adenoviral vectors in transferring genes into airway cells, with some studies showing limited success in nasal lining cells due to the absence of specific receptors.

Overall, adenoviruses hold potential as gene-delivery vehicles, but further research is needed to overcome the challenges associated with immune responses and gene transfer efficiency.

9.Guiding Principles for Gene Therapy Products:

When developing a new gene therapy product (GTP) for clinical trials, it's essential to provide detailed information about its production, testing, and quality assurance. This includes:

1. Chemistry, Manufacturing, and Control (CMC) processes

2. Good Manufacturing Practice (GMP) and Good Laboratory Practice (GLP) facilities

3. Vector components (e.g., viral or bacterial vectors)

4. Cellular components (e.g., autologous or allogeneic cells)

5. Reagents and excipients used in production

Vector Components:

- Provide detailed information about the vector's structure, genetic code, and control elements

- Describe the virus or bacteria used, including physical and chemical traits, growth characteristics, and genetic markers

Cellular Components:

- Explain the source of cells (autologous or allogeneic)

- Describe cell handling methods, including preparation, activation, growth, collection, and viability

- Detail any genetic modifications made to the cells

Reagents and Excipients:

- Provide information about reagents used in production, including quantity, source, quality, and purpose

- Explain the use of excipients in the final product, including quantity, source, and quality

By following these guiding principles, manufacturers can ensure the safety, quality, and efficacy of their gene therapy products and obtain regulatory approval for clinical trials.

10.Clinical Trial Requirements for Gene Therapy Products:

***Planning Gene Therapy Trials:**

1. Use animal models similar to humans for testing.

2. Select patients with detailed disease information and medical history.

3. Screen for pre-existing antibodies that may react to the treatment.

4. Exclude healthy volunteers and placebo groups due to risks.

Study Design:

1. Group patients by disease severity and genetic characteristics.

2. Blinding may not be possible in some cases.

Dose and Administration:

1. Determine doses based on preclinical studies or similar trials.

2. Hospitalize participants before and after treatment.

3. Monitor for immune reactions and consider temporary suppression.

Endpoints and Assessments:

1. Monitor safety and immunological reactions.

2. Measure bioactivity and gene transfer.

3. Assess functional improvements and patient experiences.

11.Conclusion:

Gene therapy has made significant progress in treating genetic disorders by modifying genes and restoring normal cellular function. Advances in technology and disease understanding have enabled its application to various conditions. Future goals include precise targeting, immune response management, and safe gene expression control, holding potential for personalized medicine and improved patient outcomes.

In the next 25 years, gene therapy is expected to:

- Deliver essential proteins

- Treat single-gene issues

- Address common diseases like heart disease and cancer

CRISPR-Cas9 technology has revolutionized genetics, enabling precise gene editing. FDA-approved gene therapy drugs and recent biotechnological advances demonstrate its growing significance in medicine. Advantages include:

- Potential for permanent cures

- Fewer side effects

- Broad applicability across medical specialties

However, challenges remain, including delivery issues, immune responses, and temporary gene expression limitations. Ongoing research and innovative strategies are needed to overcome these challenges.

Guiding principles for gene therapy product development emphasize the importance of:

- Rigorous CMC processes

- Quality assurance

- Regulatory compliance

Detailed information on vector components, cellular sources, genetic changes, and other components ensures safety and efficacy. Preclinical trials require careful consideration of animal models, administration methods, dosing, safety, and environmental impact. Clinical trials planning involves patient selection, study design, dosing, monitoring, and long-term follow-up to ensure successful translation of gene therapy products into effective treatments.

12.References-

1.Salameh JW, Zhou L, Ward SM, Santa Chalarca CF, Emrick T, Figueiredo ML. Polymer-mediated gene therapy: Recent advances and merging of delivery techniques. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology. 2020 Mar;12(2):e1598.

2.Wei Chen, Yang Hu, Dianwen Ju,Gene therapy for neurodegenerative disorders: advances, insights and prospects,Acta Pharmaceutica Sinica B,Volume 10, Issue 8,2020,Pages 1347-1359,ISSN 2211-3835,

3.Dunbar, Cynthia, et al. "Gene Therapy Comes of Age." Science, 2018, https://doi.org/aan4672. Accessed 4 Aug. 2023.

4.akki rajesh. A REVIEW ARTICLE ON GENE THERAPY. JDDT [Internet]. 15Jul.2019 [cited 23Jul.2023];9(4):688-92. Available from: https://jddtonline.info/index.php/jddt/article/view/3173

5.Danaeifar, M. Recent advances in gene therapy: genetic bullets to the root of the problem. Clin Exp Med (2022). https://doi.org/10.1007/s10238-022-00925-x

6.Ricobaraza, Ana, et al. "High-capacity adenoviral vectors: expanding the scope of gene therapy." International Journal of Molecular Sciences 21.10 (2020): 3643.

7.Rangel Gonçalves, G. A., & Paiva, M. A. (2017). Gene therapy: Advances, challenges and perspectives. Einstein, 15(3), 369-375. https://doi.org/10.1590/S1679-45082017RB4024

8.McCain J. The future of gene therapy. Biotechnol Healthc. 2005 Jun;2(3):52-60. PMID: 23393464; PMCID: PMC3564347.

9.Collins M, Thrasher A. Gene therapy: progress and predictions. Proceedings of the Royal Society B: Biological Sciences. 2015 Dec 22;282(1821):20143003.

10.Kumar SR, Markusic DM, Biswas M, High KA, Herzog RW. Clinical development of gene therapy: results and lessons from recent successes. Molecular Therapy-Methods & Clinical Development. 2016 Jan 1;3.

11.Nidhi S, Anand U, Oleksak P, Tripathi P, Lal JA, Thomas G, Kuca K, Tripathi V. Novel CRISPR-Cas Systems: An Updated Review of the Current Achievements, Applications, and Future Research Perspectives. Int J Mol Sci. 2021 Mar 24;22(7):3327. doi: 10.3390/ijms22073327. PMID: 33805113; PMCID: PMC8036902.

12.Ma, Y., Zhang, L., & Huang, X. (2014). Genome modification by CRISPR/Cas9. The FEBS Journal, 281(23), 5186-5193. https://doi.org/10.1111/febs.13110

13.Shahryari, A., Burtscher, I., Nazari, Z., & Lickert, H. (2021). Engineering Gene Therapy: Advances and Barriers. Advanced Therapeutics, 4(9), 2100040. https://doi.org/10.1002/adtp.202100040

14.Rangarajan, P. N., and G. Padmanaban. "Gene Therapy: Principles, Practice, Problems and Prospects." Current Science, vol. 71, no. 5, 1996, pp. 360–68. JSTOR, http://www.jstor.org/stable/24099612. Accessed 1 Aug. 2023.

15.https://www.researchgate.net/publication/304988303_An_overview_of_the_history_applications_advantages_disadvantages and_prospects_of_gene_therapy

16.Manzari MT, Shamay Y, Kiguchi H, Rosen N, Scaltriti M, Heller DA. Targeted drug delivery strategies for precision medicines. Nature Reviews Materials. 2021 Apr;6(4):351-70.

17.Rangel Gonçalves, G. A., & Paiva, M. A. (2017). Gene therapy: Advances, challenges and perspectives. Einstein, 15(3), 369-375. https://doi.org/10.1590/S1679-45082017RB4024

18.Rangarajan, P. N., and G. Padmanaban. "Gene Therapy: Principles, Practice, Problems and Prospects." Current Science, vol. 71, no. 5, 1996, pp. 360–68. JSTOR, http://www.jstor.org/stable/24099612. Accessed 1 Aug. 2023

19.Karpati, G., & Lochmüller, H. (1997). The scope of gene therapy in humans: Scientific, safety and ethical considerations. Neuromuscular Disorders, 7(5), 273-276. https://doi.org/10.1016/S0960-8966(97)00051-5

20.Das SK, Menezes ME, Bhatia S, Wang XY, Emdad L, Sarkar D, Fisher PB. Gene Therapies for Cancer: Strategies, Challenges and Successes. J Cell Physiol. 2015 Feb;230(2):259-71. doi: 10.1002/jcp.24791. PMID: 25196387; PMCID: PMC4363073

21.Cross D, Burmester JK. Gene therapy for cancer treatment: past, present and future. Clin Med Res. 2006 Sep;4(3):218-27. doi: 10.3121/cmr.4.3.218. PMID: 16988102; PMCID: PMC1570487.

22.Belete TM. The Current Status of Gene Therapy for the Treatment of Cancer. Biologics. 2021;15:67-77 https://doi.org/10.2147/BTT.S302095

23.Jack A. Roth, Richard J. Cristiano. Gene Therapy for Cancer: What Have We Done and Where Are We Going? JNCI: Journal of the National Cancer Institute. 1997 Jan 1;89(1):21-39. https://doi.org/10.1093/jnci/89.1.21

24.Giamas G, Gagliano T. Cancer gene therapy 2020: highlights from a challenging year. Cancer Gene Ther. 2022 Jan;29(1):1-3. doi: 10.1038/s41417-021-00340-6. Epub 2021 May 7. PMID: 33963297; PMCID: PMC8103066.

25.McCrudden CM, McCarthy HO. Current status of gene therapy for breast cancer: progress and challenges. The application of clinical genetics. 2014 Nov 10:209-20.

26.Zhang L, Liang L, Qiao L, Chen X, Zhang X, Yang R, Jiang L, Xu Z. Stem Cells in Cancer Therapy: Opportunities and Challenges. Oncotarget. 2017;8(43):75756-75766. doi: 10.18632/oncotarget.20798 . Accessed August 4, 2023.

27.Mendell, Jerry R., et al. "Current clinical applications of in vivo gene therapy with AAVs." Molecular Therapy 29.2 (2021): 464-488.

28.Harrison GS, Glode LM. Current challenges of gene therapy for prostate cancer. ONCOLOGY-WILLISTON PARK THEN HUNTINGTON-. 1997 Jun 1;11:845-55.

29.Wilson JM. Adenoviruses as gene-delivery vehicles. New England Journal of Medicine. 1996 May 2;334(18):1185-7.

30.Sivagourounadin K, Ravichandran M, Rajendran P. National guidelines for gene therapy product (2019): A road-map to gene therapy products development and clinical trials. Perspect Clin Res. 2021 Jul-Sep;12(3):118-125. Doi: 10.4103/picr.PICR_189_20. Epub 2021 Mar 26. PMID: 34386375; PMCID: PMC8323560. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8323560/